Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.

The big winners of the night were AstraZeneca and Roche as pharma, biotech and allied industries came together online on 2 December to celebrate during a ceremony hosted by Ed Balls.

COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called  “responsible progress.”